Characteristics of human Ewing/PNET sarcoma models

Annals of Saudi Medicine

Volumn 31, Issue 2, 2011, Pages 174-182

  Teicher, Beverly A ^a   Bagley, Rebecca G ^a   Rouleau, Cecile ^a   Kruger, Ariel ^a   Ren, Yi ^a   Kurtzberg, Leslie ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CARBOPLATIN; CD146 ANTIGEN; CELL SURFACE PROTEIN; CHEMOKINE RECEPTOR CXCR2; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ENDOSIALIN; ETOPOSIDE; IFOSFAMIDE; INTERLEUKIN 8; PAZOPANIB; RAMUCIRUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN; VINCRISTINE;

CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SIZE; CELL STRAIN HEK293; DRUG MEGADOSE; EWING SARCOMA; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEUROECTODERMAL TUMORS, PRIMITIVE; SARCOMA, EWING'S;

EID: 79953210083     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.78206     Document Type: Review

References (74)

1. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nature Rev Cancer 2008;8:288-98. (Pubitemid 351430865)
2. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010;11:184-92.
3. Windsor R, Strauss S, Seddon B, Whelan J. Experimental therapies in Ewing's sarcoma. Expert Opin Investig Drugs 2009;18:143-59.
4. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to geneome complexity. Nature Med 2010;16:781-7.
5. Randall RL, Lessnick SL, Jones KB, Gouw LG, Cummings JE, Cannon-Albright L, et al. Is there a predisposition gene for Ewing's sarcoma? J Oncol 2010;2010:1-6.
6. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing's sarcoma family of tumors: Current management. Oncologist 2006;11:503-19. (Pubitemid 43788277)
7. Janknecht R. EWS-ETS oncoproteins: The linchpins of Ewing tumors. Gene 2005;363:1-14. (Pubitemid 41691887)
8. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gyrpide J. Advances in Ewing's sarcoma research: Where are we now and what lies ahead? Cancer Res 2009;69:7140-50.
9. Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, et al. Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investing Drugs 2008;17:1703-15.
10. Teicher BA. Human tumor xenografts and mouse models of human tumors: Rediscovering the models. Exp Opin Drug Discovery 2009;4:1295-305.
11. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nature Protocols 2007;2:247-50. (Pubitemid 47040037)
12. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, et al. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 2008;14:4572-83.
13. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, et al. Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 2007;67:32-40. (Pubitemid 46142757)
14. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-40. (Pubitemid 350022448)
15. Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer 2008;50:703-6. (Pubitemid 351155868)
16. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 2004;64:5415-24. (Pubitemid 39006564)
17. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, Martinez-Delgado B, Urioste M, Cigudosa JC, et al. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 2003;141:138-42. (Pubitemid 36269213)
18. Coleman N, Roberts I. Re: Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 2004;148:86. (Pubitemid 38018887)
19. Rouleau C, Curiel M, Weber W, Smale R, Kurtzberg L, Mascarello J, et al. Endosialin protein expression and therapeutic targetpotential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res 2008;14:7223-36.
20. DuBois SG, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma. Cancer 2010;116:749-57.
21. Teicher BA. A systems approach to cancer therapy (antiangiogenics + standard cytotoxics mechanism(s) of interaction. Cancer Metastasis Rev 1996;15:247-72.
22. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular enothelial growth factor. Cancer Res 2000;60:6253-8.
23. Gerber HP, Ferrara N. Pharmacology and pharmacodynamic of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80. (Pubitemid 40216420)
24. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, et al. Vascular endothelail growth factor: A therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer res 2005;11:2364-78. (Pubitemid 40490198)
25. Yang SX. Bevacizumab and breast cancer: Current therapeutic progress and future. Exp Rev Anticancer ther 2009;9:1715-25.
26. Higa GM. Breast cancer: Beyond the cutting edge. Expert Opin Pharmacother 2009;10:2479-98.
27. Sarmiento R, D'Andrea M, Cacciamani F, Salerno F, Gasparini G. Antiangiogenic therapies in breast cancer. Curr Opin Investig Drugs 2009;10:1334-45.
28. Roy V, Perez EA. Bioloigc therapy of breast cancer: Focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res Treat 2009;116:31-8.
29. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab 9IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-7.
30. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 2008;47:176-86.
31. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
32. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
33. Sternberg CN, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, et al. A randomized, double-blind phase III study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009;27:5431-8.
34. Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatment on metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2009;9:1793-805.
35. Zhu AX, Raymond E. Early development of sunitinib in heptacellular carcinoma. Exp Rev Anticancer Ther 2009;9:143-50.
36. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-92. (Pubitemid 352039741)
37. Theo-Anton N, Faivre S, Dreyer C, Raymond E. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumors and renal cancer. Drug Safety 2009;32:717-34.
38. Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007;59:183-95. (Pubitemid 44885148)
39. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, Iacobelli S. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008;270:229-33.
40. Ferrara N. VEGF-A: A critical regulator of blood vessel growth. Eur Cytokine Netw 2009;20:158-63.
41. Staton CA, Brown NJ, Reed MW. Current status and future prospects for anti-angiogenic therapies in cancer. Expm Opin Drg Discov 2009;4:961-79.
42. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008;28:1928-36.
43. Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival and angiogenesis. Clin Cancer Res 2009;15:2380-6.
44. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: Decisions and indecisions. Cancer Met Rev 2008;27:31-40.
45. Crawford S, Belajic D, Wei J, Riley JP, Dunford PJ, Bembenek S, et al. A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker. Molec Cancer Ther 2008;7:492-9. (Pubitemid 351482132)
46. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z, et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009;125:1027-37.
47. Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, et al. Snail promotes CXCR2 ligand-dependent tumor progression in noon-small cell lung carcinoma. Clin Cancer Res 2009;15:6820-9.
48. Neri F, Puviani L, Tsivian M, Prezzi D, Pacile V, Cavallari G, et al. Protective effect of an inhibitor of interleukin-8 (meraxin) from ischemia and reperfusion injury in a rat model of kidney transplantation. Transplant Proc 2007;39:1771-2. (Pubitemid 47198787)
49. Rettig WJ, Garin-Chesa P, Healy JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 1992;89:10832-6.
50. Teicher BA. Newer vascular targets: Endosialin (review). Int J Oncol 2007;30:305-12.
51. Bagley RG. Endosialin: From vascular target to biomarker for human sarcomas. Biomarkers Med 2009;3:589-604.
52. Opavsky R, Haviernik P, Jurkovicova D, Garin MT, Copeland NG, Gilbert DJ, et al. Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J Biol Chem 2001;276:38795-807.
53. Dolznig H, Schwiefer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D, et al. Characterization of cancer stroma markers: In silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 2005;5:10-9.
54. Lax S, Hou TZ, Jenkinson E, Salmon M, MacFadyen JR, Isacke CM, et al. CD248/Endosialin is dynamically expressed on a subset of stromal cells during lymphoid tissue development, splenic remodeling and repair. FEBS Lett 2007;581:3550-6. (Pubitemid 47048202)
55. Lax S, Hardie DL, Wilson A, Douglas MR, Anderson G, Huso D, et al. The pericyte and stromal cell marker CD248 (endosialin) is required for efficient lymph node expansion. Eur J Immunol 2010;40:1884-9.
56. MacFadyen JR, Haworth O, Robertson D, Hardie D, Webster MT, Morris HR, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett 2005;579:2569-75. (Pubitemid 40615660)
57. MacFadyen J, Savage K, Wienke D, Isacke CM. Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr Patterns 2007;7:363-9. (Pubitemid 44835271)
58. Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, et al. Mouse endosialin, a C-type lectin-like cell surface receptor: Expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun 2006;6:10-21.
59. Rupp C, Dolznig H, Puri C, Schweifer N, Sommergruber W, Kraut N, et al. Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin. Diagn Mol Pathol 2006;15:35-42.
60. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202. (Pubitemid 30650733)
61. Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi HP, Garin-Chesa P, et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001;276:7408-14.
62. Brady J, Neal J, Sadakar N, Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol. 2004;63:1274-83. (Pubitemid 39603399)
63. Carson-Walter EB, Winnans BN, Whiteman MC, Liu Y, Jarvels S, Haapasalo H, et al. Characterization of TEM1/endosialin in human and murine brain tumors. BMC Cancer 2009;9:417.
64. Tentori L, Vergati M, Muzi A, Levati L, Ruffini F, Forini O, et al. Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. Int J Oncol 2005;27:525-35.
65. Huber MA, Kraut N, Schweifer N, Dolznig H, Peter RU, Schubert RD, et al. Expression of stromal cell markers in distinct compartments of human skin cancers. J Cutan Pathol 2006;33:145-55.
66. Virgintino D, Girolamo F, Errede M, Capobianco C, Rovertson D, Stallcup WB, et al. An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis. Angiogenesis 2007;10:35-45. (Pubitemid 46356222)
67. Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, et al.Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors.Proc Natl Acad Sci USA. 2006;103:3351-6. (Pubitemid 43346473)
68. Battle TE, Nguyen C, Bagley RG, Kataoka S, Honma N, Brondyk W, et al. TEM1/endosialin participates in cell matrix and cell-cell adhesion interactions. Proc Amer Assoc Cancer Res 2007;48.
69. Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E, et al. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci USA 2007;104:17965-70. (Pubitemid 350210804)
70. Tomkowicz B, Rybinski K, Sebeck D, Sass P, Nicolaides NC, Grasso L, et al. Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biol Ther 2010;9:908-15.
71. Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, et al. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast cancer Res 2009;11:R1.
72. Ohradanova A, Gradin K, Barathova M, Zatovicova M, Holotnakova T, Kopacek J, et al. Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. Br J Cancer 2008;99:1348-56.
73. Thornton K. Chemotherapeutic management of soft tissue sarcoma. Surg Clin North Am 2008;88:647-60. (Pubitemid 351734512)
74. Thornton K, Pesce CE, Choti MA. Multidisciplinary management of metastatic sarcoma. Surg Clin North Am 2008;88:661-72. (Pubitemid 351734516)